148 related articles for article (PubMed ID: 20103549)
1. Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
Cohen A; Rabbani A; Shah N; Alexander GC
Diabetes Care; 2010 Apr; 33(4):823-5. PubMed ID: 20103549
[TBL] [Abstract][Full Text] [Related]
2. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
Hsu JC; Ross-Degnan D; Wagner AK; Zhang F; Lu CY
Clin Ther; 2015 Jul; 37(7):1420-1432.e1. PubMed ID: 25976425
[TBL] [Abstract][Full Text] [Related]
3. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
Niyomnaitham S; Page A; La Caze A; Whitfield K; Smith AJ
BMC Health Serv Res; 2014 Apr; 14():151. PubMed ID: 24708579
[TBL] [Abstract][Full Text] [Related]
4. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
5. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
Hall GC; Smith HT; Curtis B; McMahon AD
Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
[TBL] [Abstract][Full Text] [Related]
6. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
[TBL] [Abstract][Full Text] [Related]
7. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
Leal I; Romio SA; Schuemie M; Oteri A; Sturkenboom M; Trifirò G
Br J Clin Pharmacol; 2013 Mar; 75(3):861-8. PubMed ID: 22845019
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
[TBL] [Abstract][Full Text] [Related]
10. National use of postmenopausal hormone therapy: annual trends and response to recent evidence.
Hersh AL; Stefanick ML; Stafford RS
JAMA; 2004 Jan; 291(1):47-53. PubMed ID: 14709575
[TBL] [Abstract][Full Text] [Related]
11. Increasing off-label use of antipsychotic medications in the United States, 1995-2008.
Alexander GC; Gallagher SA; Mascola A; Moloney RM; Stafford RS
Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):177-84. PubMed ID: 21254289
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM
PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
[TBL] [Abstract][Full Text] [Related]
14. Comment on: prescribing of rosiglitazone and pioglitazone following safety signals analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008.
Carracedo-MartÃnez E
Drug Saf; 2014 Dec; 37(12):1069-70. PubMed ID: 25249047
[No Abstract] [Full Text] [Related]
15. Impact of FDA black box advisory on antipsychotic medication use.
Dorsey ER; Rabbani A; Gallagher SA; Conti RM; Alexander GC
Arch Intern Med; 2010 Jan; 170(1):96-103. PubMed ID: 20065205
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.
Turner LW; Nartey D; Stafford RS; Singh S; Alexander GC
Diabetes Care; 2014 Apr; 37(4):985-92. PubMed ID: 24198301
[TBL] [Abstract][Full Text] [Related]
17. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
Jain R; Mullins CD; Lee H; Wong W
Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
[TBL] [Abstract][Full Text] [Related]
18. Approaches to treatment 1: How is type 2 diabetes actually treated?
Bloomgarden ZT
J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568
[No Abstract] [Full Text] [Related]
19. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.
Pincus HA; Tanielian TL; Marcus SC; Olfson M; Zarin DA; Thompson J; Magno Zito J
JAMA; 1998 Feb; 279(7):526-31. PubMed ID: 9480363
[TBL] [Abstract][Full Text] [Related]
20. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
[Next] [New Search]
